V. Allouchery, L. Augusto, F. Clatot
Oncologie, Vol.21, No.1, pp. 40-48, 2019, DOI:10.3166/onco-2019-0035
Abstract It has been known for a long time that circulating
tumor cells (CTC) as well as circulating tumor DNA (ctDNA)
can be detected. However, only recent technical advances
allowed evaluating the interest of CTC and ctDNA in breast
cancer. In both early and metastatic breast cancers, CTC
detection is a recognized factor for poor outcome. Nevertheless, CTC detection does not impact cancer management yet.
The use of ctDNA in daily practice will require validation by
prospective data. But ctDNA seems particularly promising
both for residual disease evaluation and identification of
tumor clones harbouring mutations (PI3KC, ESR1) and
may predict efficacy… More >
Login
Register
